Endocrine Abstracts

Metabolic associated fatty liver disease (MAFLD) is rapidly becoming a major aetiology for the development of hepatocellular carcinoma (HCC, the most common liver cancer) in the context of chronic liver disease. Current therapeutical options for MAFLD (dietetic/lifestyle intervention and/or pharmacological approaches) are still insufficient and the cellular and molecular mechanisms underlying this disease are yet to be fully understood. Our group previously reported that the n...

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing cause of hepatocellular carcinoma (HCCs); however, the molecular characteristics of MAFLD-derived HCCs are still to be elucidated. To provide novel insights in this field, we performed the first quantitative proteomic analysis of HCC samples from different aetiologies. Particularly, cytosolic and nuclear proteome of liver tissues from HCC patients (n=42; HCC vs adjacent tissue) and healthy contr...

Objectives: Previous studies have shown that metformin can reduce high-fat diet (HFD)-induced body weight gain and fat accumulation in the liver. However, the results obtained in animal models regarding the implication of metformin in the modulation of other whole-body and tissue-specific parameters, are controversial or need to be further explored. Consequently, we aimed to explore the capacity of metformin in modulating glucose/insulin metabolism, liver function, adiposity, ...

Hepatocellular carcinoma (HCC) is an aggressive tumour frequently associated to an underlying chronic liver disease. In this sense, metabolic dysfunction-associated steatotic liver disease (MASLD) is considered as a growing cause of HCC development. Considering the need of novel therapeutic approaches, and the promising data about targeting the tumour microenvironment in cancer, we performed quantitative proteomics on HCC samples to characterize the components and regulators o...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the main hepatic manifestation of obesity. MASLD was recently defined as liver steatosis in the presence of at least one cardiometabolic risk factor and reduced or absent alcohol intake. MASLD prevalence is rapidly increasing, thus becoming the fastest growing aetiology of the most common primary liver cancer, hepatocellular carcinoma (HCC), and the leading cause of liver transplantation in HCC patients. Curre...

Hormonal signalling plays a key role in the progression of metabolic (dysfunction)-associated fatty liver disease (MAFLD) to hepatocellular carcinoma (HCC). However, the role of somatostatin (SST), cortistatin (CORT), neuronostatin (NST) and ghrelin systems in MAFLD-HCC progression has not yet been elucidated. We characterized the role of SST/CORT/NST and ghrelin systems in chronic liver disease and evaluated their clinical potential. The expression of the components of the SS...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality. MASLD is rapidly becoming a major aetiology for the development of hepatocellular carcinoma (HCC), the most common liver cancer. As the incidence of MASLD continues to rise, it is crucial to understand the molecular alterations that lead to HCC. Previous studies have revealed a significant alterati...

Background: Hormonal signalling plays a key role in the progression of non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). However, the role of somatostatin (SST), cortistatin (CORT), neuronostatin (NST) and ghrelin systems in NAFLD-HCC progression has not been elucidated.Objectives: To characterize the role of SST/CORT/NST and ghrelin systems in chronic liver disease and evaluate its clinical potential.Met...